Drug Pricing
Commentary
Coronavirus drug cost – Ignore critics. Here’s why the price is right
Last week, Gilead Sciences announced that it would sell a five-day course of its coronavirus drug, remdesivir, for just over $3,100. The antiviral, currently the only medication proven to speed recovery from COVID-19, received FDA approval in May. Some Democratic lawmakers and policy experts attacked remdesivir’s price as soon as it was announced. They claim that Gilead could sell the drug ...
Sally C. Pipes
July 6, 2020
Commentary
Learning The Right Lessons From The Race For An Effective Covid-19 Treatment
On June 29, 2020 Gilead announced its price for remdesivir – an antiviral medication that has shown efficacy shortening the recovery time for patients with Covid-19. This price announcement provides several important lessons for the U.S. healthcare system. First, and perhaps most important, innovation is essential for winning the war against Covid-19. ...
Wayne Winegarden
June 30, 2020
Commentary
Price controls punish U.S. innovators and economy
America’s biopharmaceutical industry dwarfs most other economic sectors. It’s one of our nation’s single biggest job creators, supporting close to a million positions across the country. And its products save countless lives each year. Yet for some reason, politicians in both parties seem determined to snuff it out by imposing ...
Sally C. Pipes
June 23, 2020
Blog
What We’re Watching – June 19
Tim Anaya – How Medicines in the U.S. are Sold In the latest video in PRI’s “Escape the Drug Pricing Maze” video, the Professor and Pete reach the most difficult part of their journey: understanding how medicines are sold. It’s a complex system that hurts patients and at times exposes ...
Pacific Research Institute
June 19, 2020
Blog
What We’re Watching – June 5
Tim Anaya – Digging Up Ways to Lower Costs for High Value but Expensive Drugs In the latest video in the “Escape the Drug Pricing Maze” video, Sage the Detective Dog digs up clues on biologics and gene therapies – drugs that offer tremendous value for patients but are some ...
Tim Anaya
June 5, 2020
Agriculture
What We’re Watching – May 22
Rowena Itchon – A Memorial Day Tribute 2020 Kerry Jackson – This Doctor Won’t Take Health Insurance – and Charges Just $35 a Visit Meet the Pittsburgh doctor who doesn’t take health care insurance and charges only $35 for most office visits. That makes him a doctor from a different era. But ...
Pacific Research Institute
May 22, 2020
Blog
What We’re Watching – May 8
Rowena Itchon – Love in the Time of Coronavirus Watch some of our front line medical personnel battling COVID-19 and helping people stay alive take a much-needed break to recreate the iconic scene from Titanic, with an usual, personal protective equipment-themed twist. Kerry Jackson – Dorothy’s Song, COVID-19 Version Somewhere, ...
Pacific Research Institute
May 8, 2020
Coronavirus
Sally Pipes – The Push for Government-Run Health Care During the Coronavirus Crisis
PRI President, CEO, and Thomas W. Smith Fellow in Health Care Studies Sally C. Pipes is back to discuss some of the health care challenges that have popped up during the coronavirus crisis, including a renewed push for single-payer and calls for prescription drug price controls and a “Buy America” ...
Pacific Research Institute
April 27, 2020
Blog
What We’re Watching – April 24
Tim Anaya – Taking a Time Machine to a Lower Drug Price Future In the latest video in the “Escape the Drug Pricing Maze” series, Professor Salvare takes Pete Paystoomuch in a time machine to learn how drugs become cheaper after higher initial costs that incentivize innovation. Then they go ...
Pacific Research Institute
April 24, 2020
Blog
COVID-19 Reminds Us That Both Innovation and Affordability Are Needed
In her March 25 Forbes editorial, Sally Pipes documented how the private sector is rising to the health challenges of the coronavirus. Whether it is Moderna launching clinical trials for a COVID-19 vaccine or Gilead Sciences investigating whether one of its medicines, Remdesivir, is effective against the coronavirus, private sector ...
Wayne Winegarden
April 21, 2020
Coronavirus drug cost – Ignore critics. Here’s why the price is right
Last week, Gilead Sciences announced that it would sell a five-day course of its coronavirus drug, remdesivir, for just over $3,100. The antiviral, currently the only medication proven to speed recovery from COVID-19, received FDA approval in May. Some Democratic lawmakers and policy experts attacked remdesivir’s price as soon as it was announced. They claim that Gilead could sell the drug ...
Learning The Right Lessons From The Race For An Effective Covid-19 Treatment
On June 29, 2020 Gilead announced its price for remdesivir – an antiviral medication that has shown efficacy shortening the recovery time for patients with Covid-19. This price announcement provides several important lessons for the U.S. healthcare system. First, and perhaps most important, innovation is essential for winning the war against Covid-19. ...
Price controls punish U.S. innovators and economy
America’s biopharmaceutical industry dwarfs most other economic sectors. It’s one of our nation’s single biggest job creators, supporting close to a million positions across the country. And its products save countless lives each year. Yet for some reason, politicians in both parties seem determined to snuff it out by imposing ...
What We’re Watching – June 19
Tim Anaya – How Medicines in the U.S. are Sold In the latest video in PRI’s “Escape the Drug Pricing Maze” video, the Professor and Pete reach the most difficult part of their journey: understanding how medicines are sold. It’s a complex system that hurts patients and at times exposes ...
What We’re Watching – June 5
Tim Anaya – Digging Up Ways to Lower Costs for High Value but Expensive Drugs In the latest video in the “Escape the Drug Pricing Maze” video, Sage the Detective Dog digs up clues on biologics and gene therapies – drugs that offer tremendous value for patients but are some ...
What We’re Watching – May 22
Rowena Itchon – A Memorial Day Tribute 2020 Kerry Jackson – This Doctor Won’t Take Health Insurance – and Charges Just $35 a Visit Meet the Pittsburgh doctor who doesn’t take health care insurance and charges only $35 for most office visits. That makes him a doctor from a different era. But ...
What We’re Watching – May 8
Rowena Itchon – Love in the Time of Coronavirus Watch some of our front line medical personnel battling COVID-19 and helping people stay alive take a much-needed break to recreate the iconic scene from Titanic, with an usual, personal protective equipment-themed twist. Kerry Jackson – Dorothy’s Song, COVID-19 Version Somewhere, ...
Sally Pipes – The Push for Government-Run Health Care During the Coronavirus Crisis
PRI President, CEO, and Thomas W. Smith Fellow in Health Care Studies Sally C. Pipes is back to discuss some of the health care challenges that have popped up during the coronavirus crisis, including a renewed push for single-payer and calls for prescription drug price controls and a “Buy America” ...
What We’re Watching – April 24
Tim Anaya – Taking a Time Machine to a Lower Drug Price Future In the latest video in the “Escape the Drug Pricing Maze” series, Professor Salvare takes Pete Paystoomuch in a time machine to learn how drugs become cheaper after higher initial costs that incentivize innovation. Then they go ...
COVID-19 Reminds Us That Both Innovation and Affordability Are Needed
In her March 25 Forbes editorial, Sally Pipes documented how the private sector is rising to the health challenges of the coronavirus. Whether it is Moderna launching clinical trials for a COVID-19 vaccine or Gilead Sciences investigating whether one of its medicines, Remdesivir, is effective against the coronavirus, private sector ...